Future of Moderna post-COVID taking shape
The biotech company Moderna, like other players who benefited from the pandemic, is facing a sharp decline in COVID vaccination. However, the American biotech’s strategy to address this drop in sales is starting to materialize with the introduction of new treatments. On Monday, they presented promising initial results in the Phase III (final stage of drug development) of their combined flu and COVID vaccine. This vaccine elicits a higher immune response compared to already authorized vaccines it was tested against.
“We have started discussions with regulatory authorities. It is a seasonal vaccination, so for the fastest countries, we can expect a market launch in the fall of 2025, for others, it will be in the fall of 2026,” explained Stéphane Bancel, CEO of Moderna. Like Spikevax, Moderna’s COVID vaccine, mRNA-1083 (the current name of this vaccine), is based on messenger RNA technology, whose efficacy was demonstrated during the pandemic. It combines elements from the COVID vaccine and the company’s flu vaccine candidate.
For just CHF 29 per month, access all our articles unlimited. Take advantage of our special offer: the first month for only CHF 9!
Reasons to subscribe to Le Temps:
– Unlimited access to all content on the website.
– Unlimited access to all content available on the mobile app.
– Sharing package of 5 articles per month.
– Digital version of the newspaper available from 10pm the night before.
– Access to supplements and T, Le Temps’ magazine, in e-paper format.
– Access to a range of exclusive benefits reserved for subscribers.
Already a subscriber? Log in.